Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Lihui Qu; Yingying Lu; Meike Ying; Bingjue Li; Chunhua Weng; Zhoutao Xie; Ludan Liang; Chuan Lin; Xian Yang; Shi Feng; Yucheng Wang; Xiujin Shen; Qin Zhou; Ying Chen; Zhimin Chen; Jianyong Wu; Weiqiang Lin; Yi Shen; Jing Qin; Hang Xu; Feng Xu; Junwen Wang; Jianghua Chen; Hong Jiang; Hongfeng Huang

doi:10.18632/oncotarget.18150

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Lihui Qu, Yingying Lu, Meike Ying, Bingjue Li, Chunhua Weng, Zhoutao Xie, Ludan Liang, Chuan Lin, Xian Yang, Shi Feng, Yucheng Wang, Xiujin Shen, Qin Zhou, Ying Chen, Zhimin Chen, Jianyong Wu, Weiqiang Lin, Yi Shen, Jing Qin, Hang XuFeng Xu, Junwen Wang, Jianghua Chen, Hong Jiang, Hongfeng Huang

Research

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.

Original language	English (US)
Pages (from-to)	81285-81294
Number of pages	10
Journal	Oncotarget
Volume	8
Issue number	46
DOIs	https://doi.org/10.18632/oncotarget.18150
State	Published - 2017

Keywords

Acute rejection
CYP3A5
FK506
Renal transplantation

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.18150

Cite this

Qu, L, Lu, Y, Ying, M, Li, B, Weng, C, Xie, Z, Liang, L, Lin, C, Yang, X, Feng, S, Wang, Y, Shen, X, Zhou, Q, Chen, Y, Chen, Z, Wu, J, Lin, W, Shen, Y, Qin, J, Xu, H, Xu, F, Wang, J, Chen, J, Jiang, H & Huang, H 2017, 'Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients', Oncotarget, vol. 8, no. 46, pp. 81285-81294. https://doi.org/10.18632/oncotarget.18150

@article{3c4fb8168fd54d7dadf23c7f570515c2,

title = "Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients",

abstract = "Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.",

keywords = "Acute rejection, CYP3A5, FK506, Renal transplantation",

author = "Lihui Qu and Yingying Lu and Meike Ying and Bingjue Li and Chunhua Weng and Zhoutao Xie and Ludan Liang and Chuan Lin and Xian Yang and Shi Feng and Yucheng Wang and Xiujin Shen and Qin Zhou and Ying Chen and Zhimin Chen and Jianyong Wu and Weiqiang Lin and Yi Shen and Jing Qin and Hang Xu and Feng Xu and Junwen Wang and Jianghua Chen and Hong Jiang and Hongfeng Huang",

note = "Funding Information: This study was supported by the National Fund",

year = "2017",

doi = "10.18632/oncotarget.18150",

language = "English (US)",

volume = "8",

pages = "81285--81294",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "46",

}

TY - JOUR

T1 - Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

AU - Qu, Lihui

AU - Lu, Yingying

AU - Ying, Meike

AU - Li, Bingjue

AU - Weng, Chunhua

AU - Xie, Zhoutao

AU - Liang, Ludan

AU - Lin, Chuan

AU - Yang, Xian

AU - Feng, Shi

AU - Wang, Yucheng

AU - Shen, Xiujin

AU - Zhou, Qin

AU - Chen, Ying

AU - Chen, Zhimin

AU - Wu, Jianyong

AU - Lin, Weiqiang

AU - Shen, Yi

AU - Qin, Jing

AU - Xu, Hang

AU - Xu, Feng

AU - Wang, Junwen

AU - Chen, Jianghua

AU - Jiang, Hong

AU - Huang, Hongfeng

N1 - Funding Information: This study was supported by the National Fund

PY - 2017

Y1 - 2017

N2 - Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.

AB - Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.

KW - Acute rejection

KW - CYP3A5

KW - FK506

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=85030635398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030635398&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18150

DO - 10.18632/oncotarget.18150

M3 - Article

C2 - 29113387

AN - SCOPUS:85030635398

SN - 1949-2553

VL - 8

SP - 81285

EP - 81294

JO - Oncotarget

JF - Oncotarget

IS - 46

ER -

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this